Skip to content
Open access

Serum FAM19A5 in newly diagnosed type 2 diabetes mellitus and its association with metabolic and inflammatory parameters

Sep 2026 · Medicine · Vol 105 · 0 citations · 26 references
Medicine

TL;DR

Serum FAM19A5 levels were lower in newly diagnosed T2DM and remained independently associated with diabetes status after adjustment for BMI, HOMA-IR, and hs-CRP, and further investigation of FAM19A5 as a molecule of potential mechanistic interest, but not as a clinically useful diagnostic biomarker is supported.

Abstract

We aimed to investigate serum levels of FAM19A5, a novel adipokine implicated in inflammation and metabolic regulation, and to examine its association with key metabolic and inflammatory markers in individuals newly diagnosed with type 2 diabetes mellitus (T2DM). This case-control study included 54 patients with newly diagnosed T2DM and 54 age- and sex-matched normoglycemic controls aged 35 to 65 years. Continuous variables were summarized according to their distributions and compared using the independent-samples t test or Mann–Whitney U test, as appropriate. Spearman rank correlation was used to examine associations in the pooled sample, with false discovery rate correction for multiple testing. Subgroup analyses were conducted by metabolic syndrome, insulin resistance, and body mass index (BMI) category. The incremental value of FAM19A5 beyond conventional markers was explored using multivariable logistic regression and DeLong comparisons of the areas under the curve (AUCs). Serum FAM19A5 was lower in the T2DM group than in controls (376.1 [312.1–577.6] vs 554.5 [365.6–1524.2] ng/L; P < .001). In the pooled sample, FAM19A5 was inversely correlated with fasting glucose (ρ = −0.266, P = .005), 2-hour oral glucose tolerance test (ρ = −0.308, P = .001), and HbA1c (ρ = −0.212, P = .028), but not with BMI, waist circumference, lipid parameters, homeostasis model assessment of insulin resistance (HOMA-IR), or high-sensitivity C-reactive protein (hs-CRP). After false discovery rate correction, the associations with fasting and 2-hour oral glucose tolerance test remained significant. Within the T2DM group, FAM19A5 was lower in patients with metabolic syndrome (P = .004), insulin resistance (HOMA-IR > 2.71; P = .023), or BMI ≥25 kg/m² (P = .021). FAM19A5 alone showed poor discrimination for T2DM (AUC: 0.684; sensitivity: 66.7%; specificity: 53.7%). Adding FAM19A5 to a model containing BMI, HOMA-IR, and hs-CRP improved model fit (likelihood-ratio χ² = 13.1, P < .001) but not discrimination (AUC: 0.920 vs 0.943; DeLong P = .154). Serum FAM19A5 levels were lower in newly diagnosed T2DM and remained independently associated with diabetes status after adjustment for BMI, HOMA-IR, and hs-CRP. Correlations with glycemic measures were weak, and FAM19A5 alone had poor discriminatory performance. These findings support further investigation of FAM19A5 as a molecule of potential mechanistic interest, but not as a clinically useful diagnostic biomarker. Larger longitudinal studies are needed.

Read PDF

Similar papers

Oct 2026

Diagnostic Value of Atherogenic Indices and Serpin B 13 in Iraqi Type II Diabetic Patients

Serum serpin B13 levels and atherogenic indices are elevated in Iraqi patients with T2DM and the strong associations of serpin B13 with FSG, HbA1c%, and the TyG index, together with its high AUC value, suggest that serpin B13 may have potential as a biomarker for identifying T2DM.

Saif J. Darwish, Shakir F. T. Alaaraji · 0 citations
Open access Oct 2026

Diabetes duration modifies the association between AIP and MAFLD in type 2 diabetes

Metabolic dysfunction-associated fatty liver disease (MAFLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM). Although several insulin resistance (IR)-related indices have been proposed as surrogate markers, their comparative performance and the influence of diabetes duration remain unclear. We...

Jia-Yue Ma, Xiao-Kang Hu, Xiao-He Liang et al. · 0 citations
Open access Sep 2026

Assessment of Serum Ferritin Levels in Patients with Type 1 and Type 2 Diabetes Mellitus

Background: Diabetes Mellitus (DM) is a metabolic disease of chronic hyperglycemia. New evidence suggests that iron metabolism, specifically serum ferritin, is involved in its pathogenesis. Objectives: To evaluate and compare serum ferritin levels in patients with Type 1 DM (T1DM), Type 2 DM (T2DM) and healthy controls...

Z. A. Nasser, Ali Nahedh Abdulameer, B. A. Abdulrahman et al. · 0 citations
Open access Oct 2026

Serum periostin as a novel biomarker of metabolic and atherogenic risk in newly diagnosed type 2 diabetes mellitus with dyslipidemia

Periostin is an extracellular matrix protein that participates in tissue remodeling and inflammation and may be related to cardiometabolic abnormalities. However, its association with metabolic and lipid disorders in newly diagnosed type 2 diabetes mellitus (T2DM) patients with dyslipidemia is poorly defined. This stud...

A. A. Jafer, H. J. Hussein, N. Hasan et al. · 0 citations
Open access Sep 2026

Diagnostic Value of Serum Interleukin-9 in Patients with Type 2 Diabetes Mellitus: A Case-Control Study from Basrah, Iraq

Background: Type 2 diabetes mellitus (T2DM) is increasingly recognized as a chronic low-grade inflammatory disorder in which immune dysregulation contributes to insulin resistance and disease progression. Interleukin-9 (IL-9), a pleiotropic cytokine of the common γ-chain family, has recently been implicated in metaboli...

Fatima Tariq, I. S. Mahmood, H. Alidrisi · 0 citations
Open access Aug 2026

ASSOCIATION OF DIETARY INFLAMMATORY INDEX WITH SYSTEMIC INFLAMMATION IN WELL-CONTROLLED TYPE 2 DIABETES MELLITUS

In adults with well-controlled T2DM, a more proinflammatory diet is associated with higher systemic inflammation, particularly elevated IL 6 levels, which suggest that dietary inflammatory potential may contribute to residual cardiometabolic risk beyond glycemic control.

B. Calıkoglu, Fatma Yiğiyoğlu Tümer, H. Hacisahinogullari et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.